Edition:
India

Voyager Therapeutics Inc (VYGR.OQ)

VYGR.OQ on NASDAQ Stock Exchange Global Select Market

10.73USD
15 Feb 2019
Change (% chg)

$0.09 (+0.85%)
Prev Close
$10.64
Open
$10.72
Day's High
$10.78
Day's Low
$10.52
Volume
55,702
Avg. Vol
135,965
52-wk High
$31.91
52-wk Low
$7.77

Latest Key Developments (Source: Significant Developments)

Neurocrine Biosciences And Voyager Therapeutics Form Strategic Development And Commercialization Collaboration
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Voyager Therapeutics Inc ::NEUROCRINE BIOSCIENCES AND VOYAGER THERAPEUTICS FORM STRATEGIC DEVELOPMENT AND COMMERCIALIZATION COLLABORATION FOR PARKINSON’S DISEASE AND FRIEDREICH’S ATAXIA.VOYAGER THERAPEUTICS INC - VOYAGER RECEIVES $165 MILLION UPFRONT, ALONG WITH FUNDING FOR ONGOING DEVELOPMENT OF EACH PROGRAM.VOYAGER THERAPEUTICS INC - VOYAGER RECEIVES UP TO $1.7 BILLION IN POTENTIAL DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS.VOYAGER THERAPEUTICS INC - NEUROCRINE BIOSCIENCES HAS AGREED TO FUND CLINICAL DEVELOPMENT OF PHASE 2-3 PIVOTAL PROGRAM FOR VY-AADC.VOYAGER THERAPEUTICS INC - NEUROCRINE BIOSCIENCES HAS AGREED TO FUND DEVELOPMENT THROUGH PHASE 1 CLINICAL TRIAL OF VY-FXN01.  Full Article

Voyager Therapeutics Provides Updates For VY-AADC Clinical Program For Parkinson's Disease
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Voyager Therapeutics Inc ::VOYAGER THERAPEUTICS PROVIDES UPDATES FOR VY-AADC CLINICAL PROGRAM FOR PARKINSON’S DISEASE.VOYAGER THERAPEUTICS INC - TO INCREASE SIZE OF RESTORE-1 PHASE 2 TRIAL AND TO CONDUCT A SIMILARLY-SIZED RESTORE-2 PHASE 3 TRIAL.VOYAGER THERAPEUTICS INC - PLANS TO SUBMIT REVISED TRIAL PROTOCOL INCLUDING INCREASE IN TARGET NUMBER OF PATIENTS IN RESTORE-1 PHASE 2 TRIAL.VOYAGER THERAPEUTICS INC - PLANNED SUBMISSION OF REVISED TRIAL PROTOCOL RESULTING IN 75 TO 100 TOTAL PATIENTS IN TRIAL.VOYAGER THERAPEUTICS INC - PLANS TO CONDUCT A STAGGERED-PARALLEL PHASE 3 TRIAL (RESTORE-2) OF SIMILAR SIZE AND DESIGN TO RESTORE-1.VOYAGER THERAPEUTICS - PLANS TO BEGIN ENROLLING PATIENTS IN RESTORE-2 IN BOTH ACTIVE PHASE 2 SITES AND ADDITIONAL SITES GLOBALLY IN FIRST HALF OF 2020.VOYAGER- IF POSITIVE, RESULTS FROM RESTORE-1 & RESTORE-2 COULD POTENTIALLY FORM BASIS FOR SUBMISSION OF BLA TO FDA FOR VY-AADC FOR PARKINSON'S DISEASE.  Full Article

Voyager Therapeutics Q2 GAAP Loss Per Share $0.80
Wednesday, 8 Aug 2018 

Aug 7 (Reuters) - Voyager Therapeutics Inc ::VOYAGER THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS.Q2 GAAP LOSS PER SHARE $0.80.Q2 EARNINGS PER SHARE VIEW $-0.67 -- THOMSON REUTERS I/B/E/S.COLLABORATION REVENUES OF $2.6 MILLION FOR Q2 OF 2018.  Full Article

Voyager Receives FDA Guidance On Development Path For VY-AADC For Parkinson’s Disease
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Voyager Therapeutics Inc ::VOYAGER THERAPEUTICS RECEIVES FDA GUIDANCE ON DEVELOPMENT PATH FOR VY-AADC FOR PARKINSON’S DISEASE AND PROVIDES CLINICAL UPDATE.VOYAGER THERAPEUTICS INC - CONTINUES TO PLAN TO SUBMIT A BLA FOR VY-AADC BASED ON ITS PIVOTAL PROGRAM AND TYPE C MEETING FEEDBACK.VOYAGER THERAPEUTICS INC - POSITIVE INTERIM RESULTS WITH VY-AADC FROM PHASE 1 POSTERIOR TRAJECTORY TRIAL.VOYAGER THERAPEUTICS - BELIEVES WRITTEN RESPONSES FROM FDA TO QUESTIONS WERE INFORMATIVE & CAN BE ADDRESSED TO SUPPORT SUBMISSION OF A BLA FOR REVIEW.  Full Article

Voyager Therapeutics Announces Longer-Term Data From Ongoing Phase 1B Trial Of VY-AADC For Advanced Parkinson’s Disease
Friday, 9 Mar 2018 

March 9 (Reuters) - Voyager Therapeutics Inc ::VOYAGER THERAPEUTICS ANNOUNCES LONGER-TERM DATA FROM ONGOING PHASE 1B TRIAL OF VY-AADC FOR ADVANCED PARKINSON’S DISEASE.VOYAGER THERAPEUTICS - ‍PIVOTAL PHASE 2-3 PROGRAM REMAINS ON TRACK TO DOSE FIRST PATIENT MID-2018​.  Full Article

Voyager Therapeutics Announces FDA Clearance Of Investigational NDA For VY-AADC
Tuesday, 23 Jan 2018 

Jan 23 (Reuters) - Voyager Therapeutics Inc ::VOYAGER THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR VY-AADC FOR ADVANCED PARKINSON’S DISEASE.VOYAGER THERAPEUTICS INC - CONTINUE TO PLAN TO DOSE FIRST PATIENT IN PIVOTAL PHASE 2-3 PROGRAM FOR ADVANCED PARKINSON'S DISEASE DURING Q2.  Full Article

BB Biotech Reports 5.6% Passive Stake In Voyager Therapeutics
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - BB Biotech Ag::BB BIOTECH AG REPORTS 5.6% PASSIVE STAKE IN VOYAGER THERAPEUTICS AS OF JAN 3 - SEC FILING‍​.  Full Article

Voyager Therapeutics prices public offering of 4.50 mln common shares at $12/shr
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Voyager Therapeutics Inc :Voyager Therapeutics announces pricing of public offering of common stock.Says public offering of 4.50 million common shares priced at $12.00per share.  Full Article

Voyager Therapeutics announces proposed offering of common stock
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Voyager Therapeutics Inc :Voyager Therapeutics announces proposed offering of common stock.Voyager Therapeutics Inc - ‍commencing an underwritten public offering of $75 million of shares of its common stock​.  Full Article

Voyager Therapeutics reports Q3 GAAP loss per share $0.89
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Voyager Therapeutics Inc :Voyager Therapeutics Inc reports third quarter 2017 financial results and corporate highlights.Q3 GAAP loss per share $0.89.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Voyager Therapeutics Inc - ‍total cash, cash equivalents, and marketable debt securities as of september 30, 2017 were $125.6 million​.Voyager Therapeutics Inc - ‍continues to expect to end 2017 with total cash, cash equivalents, and marketable debt securities of about $90 million to $100 million​.Voyager Therapeutics Inc - ‍existing cash, cash equivalents, marketable debt securities will be sufficient to fund operating expenses and capex requirements into 2019​.  Full Article